Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle Di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. ChenPaul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain

Research output: Contribution to journalArticle

1588 Citations (Scopus)

Abstract

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

Original languageEnglish (US)
Pages (from-to)145-147
Number of pages3
JournalNature Medicine
Volume10
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Rectal Neoplasms
Vascular Endothelial Growth Factor A
Tumors
Blood Vessels
Antibodies
Neoplasms
Pericytes
Extracellular Fluid
Perfusion
Carcinoma
Pressure
Fluids
Bevacizumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., ... Jain, R. K. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10(2), 145-147. https://doi.org/10.1038/nm988

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. / Willett, Christopher G.; Boucher, Yves; Di Tomaso, Emmanuelle; Duda, Dan G.; Munn, Lance L.; Tong, Ricky T.; Chung, Daniel C.; Sahani, Dushyant V.; Kalva, Sanjeeva P.; Kozin, Sergey V.; Mino, Mari; Cohen, Kenneth S.; Scadden, David T.; Hartford, Alan C.; Fischman, Alan J.; Clark, Jeffrey W.; Ryan, David P.; Zhu, Andrew X.; Blaszkowsky, Lawrence S.; Chen, Helen X.; Shellito, Paul C.; Lauwers, Gregory Y.; Jain, Rakesh K.

In: Nature Medicine, Vol. 10, No. 2, 02.2004, p. 145-147.

Research output: Contribution to journalArticle

Willett, CG, Boucher, Y, Di Tomaso, E, Duda, DG, Munn, LL, Tong, RT, Chung, DC, Sahani, DV, Kalva, SP, Kozin, SV, Mino, M, Cohen, KS, Scadden, DT, Hartford, AC, Fischman, AJ, Clark, JW, Ryan, DP, Zhu, AX, Blaszkowsky, LS, Chen, HX, Shellito, PC, Lauwers, GY & Jain, RK 2004, 'Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer', Nature Medicine, vol. 10, no. 2, pp. 145-147. https://doi.org/10.1038/nm988
Willett, Christopher G. ; Boucher, Yves ; Di Tomaso, Emmanuelle ; Duda, Dan G. ; Munn, Lance L. ; Tong, Ricky T. ; Chung, Daniel C. ; Sahani, Dushyant V. ; Kalva, Sanjeeva P. ; Kozin, Sergey V. ; Mino, Mari ; Cohen, Kenneth S. ; Scadden, David T. ; Hartford, Alan C. ; Fischman, Alan J. ; Clark, Jeffrey W. ; Ryan, David P. ; Zhu, Andrew X. ; Blaszkowsky, Lawrence S. ; Chen, Helen X. ; Shellito, Paul C. ; Lauwers, Gregory Y. ; Jain, Rakesh K. / Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. In: Nature Medicine. 2004 ; Vol. 10, No. 2. pp. 145-147.
@article{975c8b33d9924e75a124b2b9b85a774f,
title = "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer",
abstract = "The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.",
author = "Willett, {Christopher G.} and Yves Boucher and {Di Tomaso}, Emmanuelle and Duda, {Dan G.} and Munn, {Lance L.} and Tong, {Ricky T.} and Chung, {Daniel C.} and Sahani, {Dushyant V.} and Kalva, {Sanjeeva P.} and Kozin, {Sergey V.} and Mari Mino and Cohen, {Kenneth S.} and Scadden, {David T.} and Hartford, {Alan C.} and Fischman, {Alan J.} and Clark, {Jeffrey W.} and Ryan, {David P.} and Zhu, {Andrew X.} and Blaszkowsky, {Lawrence S.} and Chen, {Helen X.} and Shellito, {Paul C.} and Lauwers, {Gregory Y.} and Jain, {Rakesh K.}",
year = "2004",
month = "2",
doi = "10.1038/nm988",
language = "English (US)",
volume = "10",
pages = "145--147",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

AU - Willett, Christopher G.

AU - Boucher, Yves

AU - Di Tomaso, Emmanuelle

AU - Duda, Dan G.

AU - Munn, Lance L.

AU - Tong, Ricky T.

AU - Chung, Daniel C.

AU - Sahani, Dushyant V.

AU - Kalva, Sanjeeva P.

AU - Kozin, Sergey V.

AU - Mino, Mari

AU - Cohen, Kenneth S.

AU - Scadden, David T.

AU - Hartford, Alan C.

AU - Fischman, Alan J.

AU - Clark, Jeffrey W.

AU - Ryan, David P.

AU - Zhu, Andrew X.

AU - Blaszkowsky, Lawrence S.

AU - Chen, Helen X.

AU - Shellito, Paul C.

AU - Lauwers, Gregory Y.

AU - Jain, Rakesh K.

PY - 2004/2

Y1 - 2004/2

N2 - The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

AB - The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

UR - http://www.scopus.com/inward/record.url?scp=11144354392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354392&partnerID=8YFLogxK

U2 - 10.1038/nm988

DO - 10.1038/nm988

M3 - Article

C2 - 14745444

AN - SCOPUS:11144354392

VL - 10

SP - 145

EP - 147

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -